{
  "docId": "019de073-79f3-7749-b6d9-2feecaaa4d92",
  "docSlug": "3bbd721bd246637706dab09d5c4f3165",
  "documentTitle": "Apexigen | Investor Presentation Deck | 27 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 27,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a three-pillar structure supported by a foundational platform.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-79f3-7749-b6d9-2feecaaa4d92/25",
  "deckHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92",
  "deckJsonHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92.json",
  "deckAnchorHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.52,
        "x": 0.24,
        "y": 0.73
      },
      "kind": "callout",
      "text": "VALIDATED APXiMAB™ ANTIBODY DISCOVERY PLATFORM",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33ebc959-8815-44bb-98ff-58d580985302",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.37,
        "y": 0.35
      },
      "kind": "list",
      "text": "PROPRIETARY PIPELINE: Pipeline of Candidates. APX601 TNFR2: IND ready. APX801 NK cell engager. Additional research programs.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8e6dfa7-571e-45d8-bed9-0145600cad2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "list",
      "text": "VALIDATING PARTNERSHIPS: 5 Licensees. Apexigen receiving Royalties on sales of Novartis' Beovu product.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3eb9952-cb4b-45c6-91eb-4b8ca52b5062",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.09,
        "y": 0.35
      },
      "kind": "list",
      "text": "LEAD PRODUCT: Sotigalimab/APX005M. Potentially first-in-class and best-in-class CD40 agonist with clinical immune-priming and efficacy data.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4c9f825-ff3d-4142-ba25-0c0bdf77b149",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.26,
        "x": 0.37,
        "y": 0.08
      },
      "kind": "title",
      "text": "Apexigen",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "963eeca6-9c3e-4ef4-b73c-911ba67bd2a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "title",
      "text": "Leader in Discovering and Developing Innovative Therapeutic Antibodies Against Cancer",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96ee4d96-4257-4ef8-8b62-d841904fd293",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "b7fdad93-427d-40df-826f-179a91ef6f2b",
      "evidence": "list/bullet: LEAD PRODUCT: Sotigalimab/APX005M. Potentially first-in-class and best-in-class CD40 agonist with clinical immune-priming and efficacy data.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "three-pillar-model",
      "slug": null,
      "matchId": "e68c4352-f573-4e1a-b1a6-bf83aba81985",
      "evidence": "The slide organizes information into three distinct columns (Lead Product, Pipeline, Partnerships) supported by a base.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}